Bullinger M, et al. - From both the adolescent and the parent perspective, researchers ascertained if growth hormone (GH), aromatase inhibitors (AI), or their combination impacts the quality of life (QoL) of adolescent males with idiopathic short stature (ISS). Study participants included 76 pubertal males with ISS who received AI, GH, or AI/GH for 24 months. They used the condition-specific Quality of Life in Short Stature Youth questionnaire to evaluate QoL. According to this randomized open-label comparator trial, GH and AI/GH treatment has been associated with improved QoL scores as measured from both the patients’ and the parents’ perspectives, implying that the improved growth resulting from the use of these growth-promoting therapies has advantageous psychosocial effects in adolescent males with ISS followed for 24 months.